ACADIA Pharmaceuticals Other Current Assets Over Time
| ACAD Stock | USD 16.32 0.03 0.18% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out ACADIA Pharmaceuticals Performance and ACADIA Pharmaceuticals Correlation. ACADIA |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ACADIA Pharmaceuticals. If investors know ACADIA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ACADIA Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 28.347 | Earnings Share 0.78 | Revenue Per Share 5.622 | Quarterly Revenue Growth 0.183 | Return On Assets 0.0872 |
The market value of ACADIA Pharmaceuticals is measured differently than its book value, which is the value of ACADIA that is recorded on the company's balance sheet. Investors also form their own opinion of ACADIA Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is ACADIA Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ACADIA Pharmaceuticals' market value can be influenced by many factors that don't directly affect ACADIA Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ACADIA Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if ACADIA Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ACADIA Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Other Current Assets Analysis
Compare ACADIA Pharmaceuticals and related stocks such as Madrigal Pharmaceuticals, Viking Therapeutics, and Sarepta Therapeutics Other Current Assets Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MDGL | 834 K | 561 K | 786 K | 765 K | 1.7 M | 1.2 M | 708 K | 485 K | 1.5 M | 1.2 M | 2 M | 2.7 M | 2.6 M | 3.1 M | 3.3 M |
| VKTX | 17.8 K | 17.8 K | 17.8 K | 17.8 K | 17.8 K | 1.1 M | 824.3 K | 1.3 M | 613 K | 7.9 M | 7.7 M | 8.4 M | 11.6 M | 5.1 M | 4.9 M |
| SRPT | 100 K | 5.3 M | 1.5 M | 3.1 M | 1.6 M | 1.2 M | 914 K | 36.5 M | 77.8 M | 5.2 M | 4.1 M | 6.1 M | 108.1 M | 140.5 M | 147.5 M |
| HEPA | 164.4 K | 164.4 K | 164.4 K | 164.4 K | 164.4 K | 681.2 K | 491 K | 210.2 K | 135.6 K | 465.7 K | 1.9 M | 6.1 M | 5.3 M | 2.7 M | 2 M |
| PTCT | 722 K | 3.4 M | 855.8 K | 1.6 M | 3.9 M | 5.9 M | 4.7 M | 6.7 M | 9.2 M | 17.9 M | 78.9 M | (126.3 M) | 105.7 M | 150.3 M | 157.8 M |
| RVPH | 69.6 K | 69.6 K | 69.6 K | 69.6 K | 69.6 K | 69.6 K | 69.6 K | 69.6 K | 69.6 K | 69.6 K | 69.6 K | 1.7 M | 403.8 K | 332.9 K | 504.5 K |
| ATHA | 74 K | 74 K | 74 K | 74 K | 74 K | 74 K | 74 K | 74 K | 74 K | 97 K | 6.4 M | 4.7 M | 6 M | 5.7 M | 4.2 M |
| FBIO | 5 K | 215 K | 393 K | 510 K | 702 K | 1.6 M | 9.1 M | 12.7 M | 6.7 M | 4.1 M | 12 M | 7.1 M | 9.7 M | 10.5 M | 5.5 M |
| CABA | 977 K | 977 K | 977 K | 977 K | 977 K | 977 K | 977 K | 977 K | 977 K | 4.3 M | 1.9 M | 2.3 M | 2.3 M | 3.2 M | 2.8 M |
| TERN | 162 K | 162 K | 162 K | 162 K | 162 K | 162 K | 162 K | 162 K | 162 K | 461 K | 3.3 M | 1.9 M | 2.1 M | 4 M | 2.2 M |
| AKRO | 40 K | 40 K | 40 K | 40 K | 40 K | 40 K | 40 K | 40 K | 1.2 M | 1.6 M | 5.9 M | 10.6 M | 7.4 M | 10 M | 5.8 M |
| KRYS | 246 K | 246 K | 246 K | 246 K | 246 K | 246 K | 246 K | 19 K | 889 K | 2.2 M | 7.6 M | 8.3 M | 4.6 M | 6.7 M | 4.2 M |
| BPMC | 461 K | 461 K | 461 K | 461 K | 1 M | 4.3 M | 2.7 M | 12.1 M | 5.8 M | 379.4 M | 22 M | 18.1 M | 35 M | 33.4 M | 51.4 M |
ACADIA Pharmaceuticals and related stocks such as Madrigal Pharmaceuticals, Viking Therapeutics, and Sarepta Therapeutics Other Current Assets description
Assets expected to be converted into cash, sold, or consumed either in one year or in the operating cycle, which are not included under standard current asset categories.My Equities
My Current Equities and Potential Positions
| ACADIA Pharmaceuticals | ACAD |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | California; U.S.A |
| Exchange | NASDAQ Exchange |
USD 16.32
Check out ACADIA Pharmaceuticals Performance and ACADIA Pharmaceuticals Correlation. For information on how to trade ACADIA Stock refer to our How to Trade ACADIA Stock guide.You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
ACADIA Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.